Literature DB >> 16304183

Pitfalls in estimating piperaquine elimination.

Joel Tarning1, Niklas Lindegårdh, Anna Annerberg, Thida Singtoroj, Nicholas P J Day, Michael Ashton, Nicholas J White.   

Abstract

By using a sensitive new assay, the terminal elimination half-life of the antimalarial piperaquine in a healthy volunteer was estimated to be 33 days, which is longer than estimated previously. This result illustrates the importance of extended sampling duration and sensitive assay methodologies in characterizing the disposition of slowly eliminated antimalarial drugs.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16304183      PMCID： PMC1315981          DOI： 10.1128/AAC.49.12.5127-5128.2005

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  8 in total

1.  High throughput assay for the determination of piperaquine in plasma.

Authors:  N Lindegårdh; N J White; N P J Day
Journal:  J Pharm Biomed Anal       Date:  2005-09-15       Impact factor: 3.935

2.  Randomized, controlled dose-optimization studies of dihydroartemisinin-piperaquine for the treatment of uncomplicated multidrug-resistant falciparum malaria in Thailand.

Authors:  Elizabeth A Ashley; Srivicha Krudsood; Lucy Phaiphun; Siripan Srivilairit; Rose McGready; Wattana Leowattana; Robert Hutagalung; Polrat Wilairatana; Alan Brockman; Sornchai Looareesuwan; Francois Nosten; Nicholas J White
Journal:  J Infect Dis       Date:  2004-10-18       Impact factor: 5.226

3.  The single dose kinetics of chloroquine and its major metabolite desethylchloroquine in healthy subjects.

Authors:  M Frisk-Holmberg; Y Bergqvist; E Termond; B Domeij-Nyberg
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

4.  Automated solid-phase extraction method for the determination of piperaquine in whole blood by rapid liquid chromatography.

Authors:  N Lindegårdh; M Ashton; Y Bergqvist
Journal:  Ther Drug Monit       Date:  2003-10       Impact factor: 3.681

5.  Dihydroartemisinin-piperaquine against multidrug-resistant Plasmodium falciparum malaria in Vietnam: randomised clinical trial.

Authors:  Tinh Hien Tran; Christiane Dolecek; Phuong Mai Pham; Thi Dung Nguyen; Thanh Truong Nguyen; Hong Thai Le; Thi Hoai An Dong; Tan Thanh Tran; Kasia Stepniewska; Nicholas J White; Jeremy Farrar
Journal:  Lancet       Date:  2004-01-03       Impact factor: 79.321

6.  On the question of dose-dependent chloroquine elimination of a single oral dose.

Authors:  L L Gustafsson; L Rombo; G Alván; A Björkman; M Lind; O Walker
Journal:  Clin Pharmacol Ther       Date:  1983-09       Impact factor: 6.875

7.  Automated solid-phase extraction method for the determination of piperaquine in capillary blood applied onto sampling paper by liquid chromatography.

Authors:  M Malm; N Lindegårdh; Y Bergqvist
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2004-09-25       Impact factor: 3.205

8.  Population pharmacokinetics of piperaquine in adults and children with uncomplicated falciparum or vivax malaria.

Authors:  Te-Yu Hung; Timothy M E Davis; Kenneth F Ilett; Harin Karunajeewa; Sean Hewitt; Mey Bouth Denis; Chiv Lim; Doung Socheat
Journal:  Br J Clin Pharmacol       Date:  2004-03       Impact factor: 4.335
  8 in total
  40 in total

1.  Pharmacokinetics of dihydroartemisinin and piperaquine in pregnant and nonpregnant women with uncomplicated falciparum malaria.

Authors:  Marcus J Rijken; Rose McGready; Aung Phae Phyo; Niklas Lindegardh; Joel Tarning; Natthapon Laochan; Hla Hla Than; Oh Mu; Aye Kyi Win; Pratap Singhasivanon; Nicholas White; François Nosten
Journal:  Antimicrob Agents Chemother       Date:  2011-09-26       Impact factor: 5.191

2.  Pharmacokinetic comparison of two piperaquine-containing artemisinin combination therapies in Papua New Guinean children with uncomplicated malaria.

Authors:  Sam Salman; Madhu Page-Sharp; Kevin T Batty; Kaye Kose; Susan Griffin; Peter M Siba; Kenneth F Ilett; Ivo Mueller; Timothy M E Davis
Journal:  Antimicrob Agents Chemother       Date:  2012-04-02       Impact factor: 5.191

3.  Piperaquine resistance is associated with a copy number variation on chromosome 5 in drug-pressured Plasmodium falciparum parasites.

Authors:  Richard T Eastman; Neekesh V Dharia; Elizabeth A Winzeler; David A Fidock
Journal:  Antimicrob Agents Chemother       Date:  2011-05-16       Impact factor: 5.191

4.  Pharmacokinetics of ferroquine, a novel 4-aminoquinoline, in asymptomatic carriers of Plasmodium falciparum infections.

Authors:  Christian Supan; Ghyslain Mombo-Ngoma; Matthias P Dal-Bianco; Carmen L Ospina Salazar; Saadou Issifou; Florent Mazuir; Aziz Filali-Ansary; Christophe Biot; Daniel Ter-Minassian; Michael Ramharter; Peter G Kremsner; Bertrand Lell
Journal:  Antimicrob Agents Chemother       Date:  2012-03-19       Impact factor: 5.191

5.  Efficacy of Artequick versus artesunate-mefloquine in the treatment of acute uncomplicated falciparum malaria in Thailand.

Authors:  Noppadon Tangpukdee; Srivicha Krudsood; Vipa Thanachartwet; Chaweewan Pengruksa; Nanthaporn Phophak; Shigeyuki Kano; Guoqiao Li; Gary M Brittenham; Sornchai Looareesuwan; Polrat Wilairatana
Journal:  Southeast Asian J Trop Med Public Health       Date:  2008-01       Impact factor: 0.267

6.  Dihydroartemisinin-piperaquine versus chloroquine to treat vivax malaria in Afghanistan: an open randomized, non-inferiority, trial.

Authors:  Ghulam Rahim Awab; Sasithon Pukrittayakamee; Mallika Imwong; Arjen M Dondorp; Charles J Woodrow; Sue Jean Lee; Nicholas P J Day; Pratap Singhasivanon; Nicholas J White; Faizullah Kaker
Journal:  Malar J       Date:  2010-04-21       Impact factor: 2.979

7.  Whole-Genome Sequencing to Evaluate the Resistance Landscape Following Antimalarial Treatment Failure With Fosmidomycin-Clindamycin.

Authors:  Ann M Guggisberg; Sesh A Sundararaman; Miguel Lanaspa; Cinta Moraleda; Raquel González; Alfredo Mayor; Pau Cisteró; David Hutchinson; Peter G Kremsner; Beatrice H Hahn; Quique Bassat; Audrey R Odom
Journal:  J Infect Dis       Date:  2016-07-20       Impact factor: 5.226

8.  Pharmacokinetic properties of sulfadoxine-pyrimethamine in pregnant women.

Authors:  Harin A Karunajeewa; Sam Salman; Ivo Mueller; Francisca Baiwog; Servina Gomorrai; Irwin Law; Madhu Page-Sharp; Stephen Rogerson; Peter Siba; Kenneth F Ilett; Timothy M E Davis
Journal:  Antimicrob Agents Chemother       Date:  2009-07-20       Impact factor: 5.191

9.  Pharmacokinetics and bioequivalence evaluation of two fixed-dose tablet formulations of dihydroartemisinin and piperaquine in Vietnamese subjects.

Authors:  Nguyen Trong Chinh; Nguyen Ngoc Quang; Nguyen Xuan Thanh; Bui Dai; Jason P Geue; Russell S Addison; Thomas Travers; Michael D Edstein
Journal:  Antimicrob Agents Chemother       Date:  2008-12-01       Impact factor: 5.191

10.  Randomized trial of piperaquine with sulfadoxine-pyrimethamine or dihydroartemisinin for malaria intermittent preventive treatment in children.

Authors:  Badara Cisse; Matthew Cairns; Ernest Faye; Ousmane NDiaye; Babacar Faye; Cecile Cames; Yue Cheng; Maguette NDiaye; Aminata Collé Lô; Kirsten Simondon; Jean-Francois Trape; Oumar Faye; Jean Louis NDiaye; Oumar Gaye; Brian Greenwood; Paul Milligan
Journal:  PLoS One       Date:  2009-09-28       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.